Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1995 of 5804
-
Can an app prevent diabetes as well as a human coach?
Prevention CompletedThe purpose of this research study is to compare the effectiveness of a fully automated digital diabetes prevention program to standard of care human coach-based diabetes prevention programs for promoting clinically meaningful lifestyle changes to reduce the risk of type 2 diabet…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
Could 10 days of brain zaps ease ADHD in teens?
Symptom relief OngoingThe objective of this clinical trial is to examine whether non-invasive brain stimulation can modulate dysfunctional brain dynamics underlying adolescent ADHD to subsequently improve clinical symptoms.
Phase: NA • Sponsor: Bradley Hospital • Aim: Symptom relief
Last updated Jun 26, 2026 15:16 UTC
-
Massive dutch study reveals long COVID's lasting toll
Knowledge-focused CompletedThe CORFU study, funded by ZonMW, is a prospective, multiple, cohort study with a maximum follow-up of 24 months after COVID-19. Dutch COVID-19 patients from 7 existing prospective cohorts, aiming and designed to conduct COVID-19 research, will be included in this study. The COR…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Sleep study could unlock secrets of Parkinson's progression
Knowledge-focused Recruiting nowBioFINDER-Sleep study was established in 2021 and will include patients with early Parkinson´s disease (PD) and persons with iRBD to provide essential insights into the underlying mechanisms of the progressive neurodegenerative processes in central and peripheral nervous systems.…
Sponsor: Skane University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Common TB drug may fuel superbug resistance, study warns
Knowledge-focused OngoingTwo commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in per…
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
New asthma drug shows promise in early trial
Symptom relief CompletedThis is a randomized, placebo controlled and double blind study to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FB704A in adult patients with severe asthma. The study comprised a 4-week screening period, a 8-week treatment period and a 12-week fol…
Phase: PHASE2 • Sponsor: Oneness Biotech Co., Ltd. • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Can a shorter radiation course tame relapsed lymphoma?
Symptom relief OngoingThis study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma. Treatment radiation over 5-6 weeks is often standard of care for many people with lymphoma, but doctors leading this study aim to find out if using r…
Phase: NA • Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Kidney drug trial halted: did it help or harm?
Disease control TerminatedThe purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate \[eGFR\] decline over time) in …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New cancer drug NX-1607 enters first human trials
Disease control Recruiting nowThis is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC
-
New pill could ease ulcerative colitis symptoms
Disease control CompletedThe study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC), as well as maintenance treatment with open-label MT-1303 for up to 36 weeks.
Phase: PHASE2 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:08 UTC
-
Cancer patients who respond to avelumab can keep taking it in this Follow-Up study
Disease control OngoingThis Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelum…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Sound waves target deep brain areas to fight depression
Symptom relief CompletedObjective: Preliminary studies show that low intensity focused ultrasound (LIFU), a new type of non invasive brain stimulation, may be able to reach deep structures of the brain involved with depression and anxiety, that remain inaccessible using current forms of non-invasive bra…
Phase: NA • Sponsor: Ocean State Research Institute, Inc. • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
New hope for hemophilia: Long-Acting drug shows promise in chinese trial
Disease control CompletedThe study investigates how well the medicine called turoctocog alfa pegol (N8-GP) works in previously treated Chinese patients with severe haemophilia A. Participants will be treated with N8-GP. This is a medicine that doctors can already prescribe in other countries. The medic…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can exercise slash heart and diabetes risks in latina breast cancer survivors?
Disease control CompletedThis study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Tailored team approach shows promise for IBS sufferers
Symptom relief OngoingThis is a 12-month longitudinal intervention study in adults (18-65 years) with moderate-severe IBS (IBS-SSS ≥175) evaluating a personalized, patient-centered multidisciplinary treatment delivered in a Swedish tertiary care setting. The program includes an internet-based IBS scho…
Phase: NA • Sponsor: Linkoeping University • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New hope for toddlers with rare bleeding disorder: wilate shows promise
Disease control CompletedThe WIL-33 study aimed to determine the efficacy, pharmacokinetics, immunogenicity and safety of wilate as routine prophylaxis in up to 12 paediatric patients (eight evaluable) with severe von Willebrand Disease VWD (defined as screening von Willebrand factor ristocetin cofactor …
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with berahyaluronidase when administered as a SC injection to participants with advanced solid tumors. Participants will receive SC injections of pembrolizumab (+) berahyaluronida…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New scan could spot myeloma spots missed by standard PET
Diagnosis OngoingThe aim of our study is to confirm the relevance of PET using \[68Ga\]Ga -PentixaFor ligand, in comparison with FDG, for initial staging and therapeutic evaluation of symptomatic multiple myeloma patients in first line treatment or in relapse. The prognostic value of positive CXC…
Phase: PHASE2 • Sponsor: Nantes University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:10 UTC
-
Tiny implant shows promise for glaucoma control during cataract surgery
Disease control CompletedPrimary open-angle glaucoma (POAG) is a chronic eye disease in which the only validated treatment is to lower intraocular pressure (IOP). It is the 2nd leading cause of blindness worldwide. The iStent® inject and inject W is an implantable device that is part of a new entity of s…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail targets Hard-to-Treat gut cancers
Disease control Completed* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combi…
Phase: PHASE1, PHASE2 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC